Our results suggest that DNA-PK inhibition combined with immune adjuvants enhances tumor immunogenicity by increasing neoantigen expression and presentation resulting in a broader panel of neoantigen reactive T cells with heightened functional capacity in mice and melanoma patients. The gene discussed is PRKDC; the disease is melanoma.